NCT00326248已完成3 期
A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50mg Oral Dosing With the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 482
- 试验地点
- 1
- 主要终点
- Rates of vomiting and retching
研究概览
简要总结
This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Arm 1
Experimental
干预措施: GW679769 (casopitant) (Drug)
结局指标
主要结局
Rates of vomiting and retching
时间窗: after surgery
次要结局
- Rates of nausea. Blood test results.(after surgery)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In WomenNausea and Vomiting, PostoperativePostoperative Nausea and VomitingNCT00334152GlaxoSmithKline515
已完成
2 期
Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on HemodialysisKidney Failure, ChronicNCT00853242Genzyme, a Sanofi Company349
进行中（未招募）
3 期
A Study of FCX-007 for Recessive Dystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis BullosaNCT04213261Castle Creek Biosciences, LLC.6
已完成
1 期
The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With CancerNausea and Vomiting, Chemotherapy-InducedNCT00440128GlaxoSmithKline12
终止
2 期
A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast CancerBreast NeoplasmsNeoplasm MetastasisNCT00102895Pfizer25